Skip to content

Inspection Record

GSK Vaccines GmbH — FDA 483 Findings

US FDAInspected 2024-11-12Published 2026-10-26 5 findingsOther quality systemDeviation, CAPA, and investigationValidation and qualificationComputer system validation

Inspectors Massoud MotamedThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

There is inadequate quality oversight to assure that the Shringrix and Measles drug substances have the identity, strength, quality, and purity they purport or are represented to possess.

2Deviation, CAPA, and investigation

Deviation management is inadequate to demonstrate quality oversight of the manufacturing process, and docs not adequately identify, document, or investigate the impact to drug substances.

3Validation and qualification

Critical utilitiesr (b) (4) utilized as productL(b) (4) in the manufacture of Shingrix are not adequately qualified or routinely monitored to ensure reproducible quality.

4Computer system validation

Quality oversigflt and integrity of electronic data captured to support the manufacturing equipment, environmental monitoring, and manufacturing systems ( e.g., Process Control System) has not been established.

5Other quality system

There is a lack of data to demonstrate the quality of'Ǖhe (b) (4) J prior to use for vaccine production.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

GSK Vaccines GmbH findings history — including this company's other documentsAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.